ADMA Biologics Inc (NASDAQ:ADMA) has scheduled a conference call for 5th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.admabiologics.com
Earnings Expectation
ADMA Biologics Inc is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ADMA to report 3Q20 loss of $ 0.19 per share. For the full year, analysts anticipate top line of $ 39.75 million, while looking forward to loss of $ 0.87 per share bottom line.
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency.
